IBDEI20X ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,33913,0)
 ;;=D51.8^^154^1711^2
 ;;^UTILITY(U,$J,358.3,33913,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33913,1,3,0)
 ;;=3^Anemia,Vitamin B12 Deficiency
 ;;^UTILITY(U,$J,358.3,33913,1,4,0)
 ;;=4^D51.8
 ;;^UTILITY(U,$J,358.3,33913,2)
 ;;=^5002288
 ;;^UTILITY(U,$J,358.3,33914,0)
 ;;=D52.9^^154^1711^1
 ;;^UTILITY(U,$J,358.3,33914,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33914,1,3,0)
 ;;=3^Anemia,Folate Deficiency
 ;;^UTILITY(U,$J,358.3,33914,1,4,0)
 ;;=4^D52.9
 ;;^UTILITY(U,$J,358.3,33914,2)
 ;;=^5002293
 ;;^UTILITY(U,$J,358.3,33915,0)
 ;;=I10.^^154^1712^12
 ;;^UTILITY(U,$J,358.3,33915,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33915,1,3,0)
 ;;=3^Hypertension,Essential
 ;;^UTILITY(U,$J,358.3,33915,1,4,0)
 ;;=4^I10.
 ;;^UTILITY(U,$J,358.3,33915,2)
 ;;=^5007062
 ;;^UTILITY(U,$J,358.3,33916,0)
 ;;=I15.0^^154^1712^13
 ;;^UTILITY(U,$J,358.3,33916,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33916,1,3,0)
 ;;=3^Hypertension,Renovascular
 ;;^UTILITY(U,$J,358.3,33916,1,4,0)
 ;;=4^I15.0
 ;;^UTILITY(U,$J,358.3,33916,2)
 ;;=^5007071
 ;;^UTILITY(U,$J,358.3,33917,0)
 ;;=I13.11^^154^1712^8
 ;;^UTILITY(U,$J,358.3,33917,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33917,1,3,0)
 ;;=3^HTN Hrt & CKD w/o Hrt Failure w/ Stage 5 Chr Kidney/ESRD
 ;;^UTILITY(U,$J,358.3,33917,1,4,0)
 ;;=4^I13.11
 ;;^UTILITY(U,$J,358.3,33917,2)
 ;;=^5007069
 ;;^UTILITY(U,$J,358.3,33918,0)
 ;;=I13.2^^154^1712^7
 ;;^UTILITY(U,$J,358.3,33918,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33918,1,3,0)
 ;;=3^HTN Hrt & CKD w/ Hrt Failure w/ Stage 5 Chr Kidney/ESRD
 ;;^UTILITY(U,$J,358.3,33918,1,4,0)
 ;;=4^I13.2
 ;;^UTILITY(U,$J,358.3,33918,2)
 ;;=^5007070
 ;;^UTILITY(U,$J,358.3,33919,0)
 ;;=I70.1^^154^1712^3
 ;;^UTILITY(U,$J,358.3,33919,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33919,1,3,0)
 ;;=3^Atherosclerosis of Renal Artery
 ;;^UTILITY(U,$J,358.3,33919,1,4,0)
 ;;=4^I70.1
 ;;^UTILITY(U,$J,358.3,33919,2)
 ;;=^269760
 ;;^UTILITY(U,$J,358.3,33920,0)
 ;;=I77.3^^154^1712^2
 ;;^UTILITY(U,$J,358.3,33920,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33920,1,3,0)
 ;;=3^Arterial Fibromuscular Dysplasia
 ;;^UTILITY(U,$J,358.3,33920,1,4,0)
 ;;=4^I77.3
 ;;^UTILITY(U,$J,358.3,33920,2)
 ;;=^5007812
 ;;^UTILITY(U,$J,358.3,33921,0)
 ;;=E26.02^^154^1712^5
 ;;^UTILITY(U,$J,358.3,33921,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33921,1,3,0)
 ;;=3^Glucocorticoid-Remediable Aldosteronism
 ;;^UTILITY(U,$J,358.3,33921,1,4,0)
 ;;=4^E26.02
 ;;^UTILITY(U,$J,358.3,33921,2)
 ;;=^329904
 ;;^UTILITY(U,$J,358.3,33922,0)
 ;;=I12.9^^154^1712^14
 ;;^UTILITY(U,$J,358.3,33922,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33922,1,3,0)
 ;;=3^Hypertensive CKD Stage 1-4
 ;;^UTILITY(U,$J,358.3,33922,1,4,0)
 ;;=4^I12.9
 ;;^UTILITY(U,$J,358.3,33922,2)
 ;;=^5007066
 ;;^UTILITY(U,$J,358.3,33923,0)
 ;;=I12.0^^154^1712^15
 ;;^UTILITY(U,$J,358.3,33923,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33923,1,3,0)
 ;;=3^Hypertensive CKD Stage 5 or ESRD
 ;;^UTILITY(U,$J,358.3,33923,1,4,0)
 ;;=4^I12.0
 ;;^UTILITY(U,$J,358.3,33923,2)
 ;;=^5007065
 ;;^UTILITY(U,$J,358.3,33924,0)
 ;;=I13.0^^154^1712^6
 ;;^UTILITY(U,$J,358.3,33924,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33924,1,3,0)
 ;;=3^HTN Hrt & CKD w/ Hrt Failure w/ Stage 1-4 Chr Kidney
 ;;^UTILITY(U,$J,358.3,33924,1,4,0)
 ;;=4^I13.0
 ;;^UTILITY(U,$J,358.3,33924,2)
 ;;=^5007067
 ;;^UTILITY(U,$J,358.3,33925,0)
 ;;=I13.10^^154^1712^9
 ;;^UTILITY(U,$J,358.3,33925,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33925,1,3,0)
 ;;=3^HTN Hrt & CKD w/o Hrt Failure w/ Stage 1-4 Chr Kidney
 ;;^UTILITY(U,$J,358.3,33925,1,4,0)
 ;;=4^I13.10
